Letter to the EditorsGabapentin for ultra resistant schizophrenia with aggressive behavior
Section snippets
Acknowledgment
Dr Michel Desmurget for editing the manuscript.
References (10)
- et al.
Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up
J. Affect. Disord.
(2003) A rating scale for drug-induced akathisia
Br. J. Psychiatry
(1989)- et al.
Gabapentin: long-term anti anxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders
Can. J. Psychiatry
(1998) - et al.
Gabapentin in the Treatment of aggression associated with conduct disorder (letter)
Prim. Care Companion J. Clin. Psychiat.
(2002) Targets for antiepileptic drugs in the synapse
Med. Sci. Monit.
(2007)
Cited by (7)
Gabapentin reduces haloperidol-induced vacuous chewing movements in mice
2018, Pharmacology Biochemistry and BehaviorCitation Excerpt :The administration of GBP with other antipsychotics has been shown to improve patients with treatment-resistant schizophrenia and stabilize aggressive behavior. However, when GBP therapy ceased, these behaviors reappeared (Demily and Franck, 2008). It is known that GBP shows therapeutic benefit in vivo, but studies have not been able to describe its exact mechanism, suggesting that GBP may not have a single molecular target but rather may modulate different systems.
Clozapine resistance: Augmentation strategies
2012, European NeuropsychopharmacologyCitation Excerpt :Nonetheless, further studies are clearly needed to confirm these promising results. Other anticonvulsants, such as pregabalin and gabapentin, were reported as augmentation agents for specific symptoms or adverse events in case-studies only; although results reported were positive; it is obviously impossible to draw any conclusion about their efficacy before further investigation in clinical trials (Demily and Franck, 2008; Englisch et al., 2010; Usiskin et al., 2000). Consistently with the NMDA receptor hypo-function hypothesis of schizophrenia (Farber et al., 1999), glutamatergic agents (glycine, d-serine, d-cycloserine, ampakine CX516, memantine, N-methylglycine) were investigated in several RCTs, which overall showed inconsistent or negative results.
Association study between Disrupted-in-Schizophrenia-1 (DISC1) and Japanese patients with treatment-resistant schizophrenia (TRS)
2011, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Disruption of glutamatergic neurotransmission is considered to be a partial cause of negative symptoms and cognitive dysfunction resulting in TRS (Heresco-Levy et al., 2005; Tsai et al., 1998; Tsai et al., 1999). Patients with TRS who are treated with clozapine but who show no improvements in the clinical symptoms (stringent criteria: patients who experience no clinical, social, and/or occupational remission despite treatment with clozapine and at least two periods of treatment with distinct conventional or atypical antipsychotics) are said to have ultra-resistant schizophrenia (URS) (Demily and Franck, 2008; Mouaffak et al., 2010). Thus, TRS and URS are important subtype in schizophrenia.
Iatrogenic psychiatric-like symptoms recognition
2010, EncephaleEffect of gabapentin on sleep-deprivation-induced disruption of prepulse inhibition
2020, PsychopharmacologyBenzodiazepines in schizophrenia: Nemesis or Nirvana?
2017, Indian Journal of Psychological Medicine